NIAMS Clinical Trial Implementation Cooperative Agreement (U01) | PAR 16 447

FAQs: NIAMS Clinical Trial Implementation Cooperative Agreement (U01) (PAR-16-447)

What is the NIAMS Clinical Trial Implementation Cooperative Agreement (U01) (PAR-16-447)?

This is a National Institutes of Health (NIH) funding opportunity from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) designed to support the conduct and execution of investigator-initiated interventional clinical trials across all phases. The focus is on running the trial (implementation), not on early concept development.

What types of studies does this opportunity support?

It supports investigator-initiated interventional clinical trials across all phases that are ready to launch and carry through enrollment, intervention delivery, follow-up, data collection, and analysis.

Does the program fund early-stage trial concept development?

No. The intent is to fund trials that are ready to start implementation activities rather than early concept development. Applications should demonstrate that planning and preparation are sufficiently complete to begin execution quickly.

What does "implementation" mean in the context of this U01?

Implementation refers to the actual conduct of the clinical trial, including enrolling participants, delivering the intervention, following participants over time, collecting trial data, and completing analysis.

What is the funding mechanism and why does it matter?

The mechanism is a cooperative agreement (U01). This matters because awardees should expect a more collaborative relationship with NIAMS than under a standard research grant, including NIH scientific or programmatic involvement in monitoring progress, agreeing on milestones, and helping ensure the study stays on track.

How is a U01 cooperative agreement different from a standard research grant?

Under a U01, NIAMS typically has substantial involvement during the project. The description provided highlights monitoring progress, agreement on milestones, and efforts to ensure the study remains on schedule and aligned with expectations.

Is there usually a planning step before applying for the U01?

Yes. A key feature is a usual two-part pathway where most applicants are expected to complete an R34 planning phase first (Part 1), and then submit the U01 implementation application (Part 2).

What is the purpose of the R34 planning phase (Part 1)?

The R34 stage is generally used to complete the essential groundwork needed before launching a large clinical trial, such as finalizing the protocol, establishing study operations, confirming feasibility, developing recruitment and retention strategies, putting data and safety monitoring procedures in place, and preparing regulatory and oversight materials.

Can an investigator apply directly to the U01 without first receiving an R34?

Yes. NIAMS allows investigators to apply directly to the U01 if they can demonstrate that all necessary pre-trial planning and preparation has already been completed through other support or prior work.

What does NIAMS expect if applying directly to the U01 without an R34?

The U01 application needs to show strong readiness to start, with operational and scientific details mature enough to move into implementation quickly. The application should clearly demonstrate that the pre-trial planning work is already complete.

What scientific focus does NIAMS emphasize for supported trials?

NIAMS emphasizes hypothesis-driven trials that are positioned for high impact within NIAMS mission areas: arthritis and rheumatic diseases, musculoskeletal diseases, and skin diseases.

What does "hypothesis-driven" imply for this opportunity?

It implies the trial should be designed around a clear scientific question or hypothesis, with a structured plan to test it through an interventional clinical trial.

What does "milestone-defined" mean in this FOA?

"Milestone-defined" indicates NIAMS will look for a concrete, measurable project management framework. Examples described include enrollment targets by time period, site activation timelines, recruitment benchmarks, data quality metrics, and prespecified decision points.

Why are milestones important in a U01 cooperative agreement?

Because the U01 mechanism includes NIAMS involvement in monitoring progress and agreeing on milestones, the trial is expected to be managed against measurable targets to demonstrate it is on track.

What does "high impact" mean for NIAMS-supported clinical trials?

The description indicates high impact typically means results capable of changing clinical practice, advancing therapeutic strategies, clarifying benefits and risks of an intervention, or substantially improving understanding of treatment approaches in NIAMS-relevant conditions.

Who is eligible to apply?

Eligibility is broad and includes many U.S.-based organizations and governments. Examples listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses) as well as small businesses; and other categories.

Are specific institution types explicitly mentioned as eligible?

Yes. The FOA explicitly calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; regional organizations; eligible federal agencies; Indian/Native American tribal governments that are not federally recognized; and U.S. territories or possessions.

Are foreign (non-U.S.) organizations eligible to apply as the applicant?

No. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are not eligible to apply.

Can a U.S. applicant include foreign involvement in the project?

Yes. "Foreign components" are allowed as defined in the NIH Grants Policy Statement. This means a U.S. applicant may include certain types of foreign involvement (such as performance sites, collaborations, or resources outside the U.S.) when justified and compliant with NIH rules, even though a foreign institution cannot be the primary applicant.

What is the activity category for this opportunity?

The funding instrument is a cooperative agreement (U01) in the health activity category.

What is the CFDA number associated with this opportunity?

The CFDA number listed is 93.846.

Is this mandatory or discretionary funding?

It is categorized as discretionary funding.

What is the application closing date listed in the provided information?

The source data provided lists an original closing date of 2018-01-24.

Does the provided excerpt state an award ceiling or expected number of awards?

No. The excerpt does not specify an award ceiling or the expected number of awards.

What stage of trial readiness is NIAMS looking for under this U01?

NIAMS is looking for trials beyond planning that are prepared for full implementation, with strong readiness to start and a clear, milestone-based execution plan through enrollment, intervention delivery, follow-up, data collection, and analysis.